{"id":17962,"date":"2014-10-15T14:29:43","date_gmt":"2014-10-15T18:29:43","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/paragon-bioteck-to-exhibit-at-american-academy-of-ophthalmology-annual-meeting-in-chicago-2014-10-1015-003\/"},"modified":"2014-10-15T14:29:43","modified_gmt":"2014-10-15T18:29:43","slug":"paragon-bioteck-to-exhibit-at-american-academy-of-ophthalmology-annual-meeting-in-chicago-2014-10-1015-003","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/paragon-bioteck-to-exhibit-at-american-academy-of-ophthalmology-annual-meeting-in-chicago-2014-10-1015-003\/","title":{"rendered":"Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago"},"content":{"rendered":"

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21. <\/p>\n

Visit Paragon BioTeck at booth #4550 to view their product portfolio including the recently FDA cleared medical device Comfortear® Lacrisolve™ Absorbable Punctum Plug, indicated for medium-term occlusion therapy for up to six (6) months.<\/p>\n

The Paragon BioTeck portfolio of products are designed to protect and preserve eyesight and to deliver comfort to the eyes. Other ocular health care products showcased will include the Comfortear® Punctum Plug, EqualEyes™ Ocular Lubricant, and the preservative-free ilast® range of products containing hyaluronic acid (HA) formulated specifically for Eyelid Hygiene. <\/p>\n

About Paragon BioTeck, Inc.:<\/strong><\/p>\n

Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight.<\/p>\n

For more information on the company and its work, please visit http:\/\/www.paragonbioteck.com\/<\/a> or call 888-424-1192; or email info@paragonbioteck.com.<\/p>\n

*LOGO: Send2Press.com\/wire\/images\/14-1015-paragonbio-300dpi.jpg .<\/p>\n

Twitter: @paragonbioteck<\/p>\n

News issued by: Paragon BioTeck, Inc.<\/p>\n

\"Paragon<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/14-1015-paragonbio-500×375.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: 2014-10-1015-003 (9699) :: paragon-bioteck-to-exhibit-at-american-academy-of-ophthalmology-annual-meeting-in-chicago-2014-10-1015-003<\/small><\/p>\n

Original Keywords: American Academy of Ophthalmology, ophthalmic pharmaceuticals, Eyelid Hygiene, Punctum Plug Paragon BioTeck, Inc. Portland Oregon PORTLAND, Ore.<\/small><\/p>\n

Alternate Headline: American Academy of Ophthalmology Annual Meeting 2014 to include exhibit from Paragon BioTeck, Inc.<\/small><\/p>\n

NEWS ARCHIVE NOTE:<\/strong> this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted\/moved (and redirected) into our 3.0 platform. Also note the story “reads” counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published\/issued: Wed, 15 Oct 2014 14:29:43 +0000<\/p>\n

<\/small><\/p>\n

Original Shortcode for Story: http:\/\/i.send2press.com\/l8lt9<\/small><\/code><\/p>\n","protected":false},"excerpt":{"rendered":"

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.<\/p>\n","protected":false},"author":4650,"featured_media":17963,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[571,61,600,537,19],"tags":[],"class_list":["post-17962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-news","category-health-medical-news","category-vision-news","category-oregon-news","category-us-news","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":6837,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/17962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/4650"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=17962"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/17962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/17963"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=17962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=17962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=17962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}